CURE PHARMACEUTICAL HOLDING CORP (OTCMKTS:CURR) had an increase of 15.58% in short interest. CURR’s SI was 44,500 shares in April as released by FINRA. Its up 15.58% from 38,500 shares previously. With 55,300 avg volume, 1 days are for CURE PHARMACEUTICAL HOLDING CORP (OTCMKTS:CURR)’s short sellers to cover CURR’s short positions. The SI to CURE PHARMACEUTICAL HOLDING CORP’s float is 0.28%. It closed at $0.73 lastly. It is down 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.
Analysts expect Community Healthcare Trust Incorporated (NYSE:CHCT) to report $0.38 EPS on May, 8 after the close.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.38 EPS. CHCT’s profit would be $6.71M giving it 17.05 P/E if the $0.38 EPS is correct. After having $0.37 EPS previously, Community Healthcare Trust Incorporated’s analysts see 2.70% EPS growth. The stock increased 1.53% or $0.39 during the last trading session, reaching $25.92. About 34,045 shares traded. Community Healthcare Trust Incorporated (NYSE:CHCT) has risen 9.52% since April 17, 2017 and is uptrending. It has underperformed by 2.03% the S&P500.
Community Healthcare Trust Incorporated is a real estate investment trust that focuses on owning income-producing real estate properties associated primarily with the delivery of outpatient healthcare services in non-urban markets throughout the United States. The company has market cap of $457.95 million.
Among 4 analysts covering Community Healthcare Trust Incorporated (NYSE:CHCT), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Community Healthcare Trust Incorporated had 7 analyst reports since September 8, 2015 according to SRatingsIntel. The stock has “Buy” rating by Sandler O’Neill on Monday, February 26. As per Tuesday, September 8, the company rating was maintained by Evercore. The company was maintained on Wednesday, January 24 by Sandler O’Neill.
Cure Pharmaceutical Holding Corp., a specialty pharmaceutical and bioscience company, develops advanced oral thin films for the delivery of nutraceutical, over-the-counter , and prescription products for human and veterinary markets. The company has market cap of $17.48 million. It offers macustrip vitamin complex, ID life sleep melatonin, electrolyte, E6 berry caffeine, and hang-over relief products. It currently has negative earnings. The firm is also developing aspirin, loratadine, tadalifil, sildenafil, loperamide, vitamin B12, vitamin D3, and folic acid products.